PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma

Patrizia Mondello, Stephen M. Ansell

Research output: Contribution to journalArticlepeer-review

Abstract

The molecular classification of diffuse large B cell lymphoma has paved the way for precision medicine that targets oncogenic driver pathways and actionable mutations. In this issue of Cancer Cell, Wilson et al. execute a massive genomic analysis in order to identify putative molecular signatures linked to a differential response to ibrutinib plus R-CHOP.

Original languageEnglish (US)
JournalCancer cell
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint

Dive into the research topics of 'PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma'. Together they form a unique fingerprint.

Cite this